Skip to content
Medical Health Aged Care, Political

BCNA calls out government for failing to protect Australians from genetic discrimination while showcasing its new genomics framework.

Breast Cancer Network Australia 3 mins read
6th February, 2025
 
Breast Cancer Network Australia (BCNA) calls on the Government to immediately prioritise its promise to introduce a full ban on genetic discrimination in life insurance, ensuring all Australians can access genomic testing without fear.
 
Today, Cancer Australia launched the National Framework for Genomics in Cancer Control, which aims to integrate genomics into routine cancer care, improving outcomes through personalised medicine. BCNA welcomes the framework but condemns the Australian Government’s failure to follow through on its commitment to legislate a full ban on genetic discrimination in life insurance, a critical reform to ensure all Australians can access genetic testing without fear of financial repercussions.
BCNA contributed to the consultation that informed the National Genomics Framework and remains committed to ensuring genomic testing is accessible, equitable, and safe. However, the lack of legal protections is already creating real-world consequences. There is widespread misinformation, with many Australians wrongly believing that legislation banning genetic discrimination has already been passed. Some individuals have proceeded with genomic testing under this false assumption, potentially putting themselves at financial risk. The Government’s inaction is not just a broken promise—it is actively misleading and endangering people who rely on genomic medicine to make critical health decisions.
 
In September 2024, the Assistant Treasurer and Minister for Financial Services, the Hon. Stephen Jones MP, announced a full legislative ban on genetic discrimination in life insurance, ensuring Australians could undergo genetic testing without fear of being penalised by insurers. Despite repeated promises that this legislation would be introduced within this parliamentary term, the Government has failed to act, leaving thousands of Australians at risk.

Dr Jane Tiller, Ethical, Legal & Social Adviser, Public Health Genomics at Monash University said today, “Minister Butler has lauded the government’s national leadership in genomic medicine. But the government is nonchalant about keeping its promise to protect Australians against genetic discrimination. The issue is not solved, and is more urgent than ever. Despite repeated promises from the government in 2024 that it would introduce legislation to ban genetic discrimination in life insurance this parliamentary term, they have not done so, and it appears they do not intend to before the election.

BCNA Director of Policy, Advocacy & Support Services Vicki Durston says: “The Government has dropped the ball when it comes to protecting Australians from genetic discrimination. We have been pushing for this for years, and now, after publicly committing to a ban, they’ve gone silent. This failure impacts thousands of Australians at risk of or living with breast cancer, who should not have to choose between their health and their financial security. BCNA will not let this go—we demand action now.
The Government cannot claim progress in genomics while failing to uphold the fundamental rights of those affected by breast cancer and other genetic conditions,” said Durston. “If genomic medicine is the future, then protections against genetic discrimination must be part of that future. No more excuses. There must be action before an election is called or Australians are at unacceptable risk.”
 
 
ENDS

Available for interview:

Dr Jane Tiller, Ethical, Legal & Social Adviser, Public Health Genomics at Monash University.

Vicki Durston,BCNA Director of Policy, Advocacy & Support Services

Case studies 

 


Key Facts:

*BCNA calls out Federal Govt failed promise to ban genetic discrimination by life insurance companies

* Without the amendment to legislation the new Cancer Aust Genomic Framework leaves Australians at risk of discrimination

* Failure to lodge draft amendment before the election is called will result in an acceptable delay in protection from insurer discrimination. 

* Interviews available, including case studies

 


About us:

Breast Cancer Network Australia (BCNA) is Australia’s leading breast cancer consumer organisation. BCNA provides information and support to those diagnosed and their supporters, opportunities to connect with others going through a similar situation and work to influence a stronger healthcare system to ensure all Australians affected by breast cancer receive the very best care, treatment and support. 


Contact details:

Kellie Curtain

M: 0412339690

[email protected]

 

More from this category

  • Medical Health Aged Care
  • 09/01/2026
  • 23:40
Dark Horse Consulting Group

Bruder Consulting & Venture Group to become Dark Horse Consulting Regenerative Medicine

WALNUT CREEK, Calif. and NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, is pleased to announce the acquisition of Bruder Consulting & Venture Group (“Bruder” or “BCVG”), a strategic advisory and consulting firm with a global footprint in biotech and biopharma, known for their expertise in the discovery, development, clinical design, and regulatory approval process of biologics, devices and combination products in the orthopedic, wound care, and plastic & reconstructive surgery markets. BCVG is now a department within Dark Horse Consulting (DHC) known as…

  • Medical Health Aged Care
  • 09/01/2026
  • 23:11
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs   BEIJING & ALAMEDA, Calif.…

  • Contains:
  • Medical Health Aged Care
  • 09/01/2026
  • 17:11
MRM Health NV

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.